Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged >65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices (vol 68, pg 1074, 2019)

被引：0

作者：

Bennett, Nancy ^{[1
]}

Farley, Monica ^{[2
,3
]}

机构：

[1] Univ Rochester, Med Ctr, Rochester, NY 14627 USA

[2] Vet Affairs Med Ctr, Decatur, GA 30033 USA

[3] Emory Univ, Dept Med, Atlanta, GA 30322 USA

来源：

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT | 2020年 / 68卷 / 51-52期

关键词：

D O I：

暂无

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

引用

页码：1195 / 1195

页数：1

共 50 条

[1] Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices
Matanock, Almea
Lee, Grace
Gierke, Ryan
Kobayashi, Miwako
Leidner, Andrew
Pilishvili, Tamara
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2019, 68 (46): : 1069 - 1075
[2] Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
Tomczyk, Sara
Bennett, Nancy M.
Stoecker, Charles
Gierke, Ryan
Moore, Matthew R.
Whitney, Cynthia G.
Hadler, Stephen
Pilishvili, Tamara
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2014, 63 (37): : 822 - 825
[3] Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults With Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices
Kaye, Donald
CLINICAL INFECTIOUS DISEASES, 2013, 56 (01)
[4] Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults With Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
Bennett, Nancy M.
Whitney, Cynthia G.
Moore, Matt
Pilishvili, Tamara
Dooling, Kathleen L.
AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 (01) : 232 - 235
[5] Pneumococcal Vaccination Among Medicare Beneficiaries Occurring After the Advisory Committee on Immunization Practices Recommendation for Routine Use Of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults Aged ≥65 Years,"
Black, C. L.
Williams, W. W.
Warnock, R.
Pilishvili, T.
Kim, D.
Kelman, J. A.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2017, 66 (32): : 863 - 863
[6] Pneumococcal Vaccination Among Medicare Beneficiaries Occurring After the Advisory Committee on Immunization Practices Recommendation for Routine Use Of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults Aged ≥65 Years
Black, Carla L.
Williams, Walter W.
Warnock, Rob
Pilishvili, Tamara
Kim, David
Kelman, Jeffrey A.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2017, 66 (27): : 728 - 733
[7] Use of 13-valent Pneumococcal Conjugate Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine Among Children Aged 6-18 Years with Immunocompromising Conditions:Recommendations of the Advisory Committee on Immunization Practices
宁桂军
中国疫苗和免疫, 2014, (02) : 187 - 188
[8] Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Children Aged 6-18 Years with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
Bennett, Nancy M.
Pilishvili, Tamara
Whitney, Cynthia G.
Moore, Matthew
Gierke, Ryan
Harris, Aaron M.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2013, 62 (25): : 521 - 524
[9] Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults With Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP) (Reprinted from MMWR vol 40, pg 816, 2012)
Bennett, Nancy M.
Whitney, Cynthia G.
Moore, Matt
Pilishvili, Tamara
Dooling, Kathleen L.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 309 (04): : 334 - 336
[10] PHARMACOECONOMIC EVALUATION OF 13-VALENT PNEUMOCOCCAL CONJUGATE AND 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE IN CANADIAN ADULTS
Chuck, A.
Waye, A.
Zanotti, G.
Jacobs, P.
Kellner, J.
Tyrrell, G.
VALUE IN HEALTH, 2012, 15 (04) : A243 - A243

← 1 2 3 4 5 →

Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged &gt;65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices (vol 68, pg 1074, 2019)

Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged >65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices (vol 68, pg 1074, 2019)